Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

Eric J. Peters; Susan L. Slager; Greg D. Jenkins; Megan S. Reinalda; Holly A. Garriock; Stanley I. Shyn; Jeffrey B. Kraft; Patrick J. McGrath; Steven P. Hamilton

doi:10.1097/FPC.0b013e3283163ecd

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

Eric J. Peters, Susan L. Slager, Greg D. Jenkins, Megan S. Reinalda, Holly A. Garriock, Stanley I. Shyn, Jeffrey B. Kraft, Patrick J. McGrath, Steven P. Hamilton

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

Several reports have been published investigating the relationship between common variants in serotonin-related candidate genes and antidepressant response, and most of the results have been equivocal. We previously reported a significant association between variants in serotoninrelated genes and response to the selective serotonin reuptake inhibitor fluoxetine. Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N= 1953). None of the variants associated previously with fluoxetine response were found to be associated with citalopram response in the STAR*D sample set. Nor were any of the additional tagging SNPs found to be associated with citalopram response. An additional SNP in HTR2A (rs7997012), previously reported to be associated with outcome of citalopram treatment in this sample, but not well tagged by any of the other SNPs we studied, was also genotyped, and was associated with citalopram response (P= 0.0002), strongly supporting the previous observation in the same STAR*D sample. Our results suggest that resequencing the serotonin-related genes did not identify any additional common SNPs that have not been identified previously. It appears that genetic variation in these five genes has a marginal effect on response to citalopram, although a previously observed association was supported and awaits replication in an independent sample. Pharmacogenetics and Genomics

Original language	English (US)
Pages (from-to)	1-10
Number of pages	10
Journal	Pharmacogenetics and genomics
Volume	19
Issue number	1
DOIs	https://doi.org/10.1097/FPC.0b013e3283163ecd
State	Published - Jan 2009

Keywords

Association
Citalopram
Fluoxetine
Pharmacogenetics
Single nucleotide polymorphism

ASJC Scopus subject areas

Genetics(clinical)
General Pharmacology, Toxicology and Pharmaceutics
Genetics
Molecular Medicine
Molecular Biology

Access to Document

10.1097/FPC.0b013e3283163ecd

Cite this

@article{361b9e3af0ce4f7ab7d5053be9e3ba36,

title = "Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response",

abstract = "Several reports have been published investigating the relationship between common variants in serotonin-related candidate genes and antidepressant response, and most of the results have been equivocal. We previously reported a significant association between variants in serotoninrelated genes and response to the selective serotonin reuptake inhibitor fluoxetine. Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N= 1953). None of the variants associated previously with fluoxetine response were found to be associated with citalopram response in the STAR*D sample set. Nor were any of the additional tagging SNPs found to be associated with citalopram response. An additional SNP in HTR2A (rs7997012), previously reported to be associated with outcome of citalopram treatment in this sample, but not well tagged by any of the other SNPs we studied, was also genotyped, and was associated with citalopram response (P= 0.0002), strongly supporting the previous observation in the same STAR*D sample. Our results suggest that resequencing the serotonin-related genes did not identify any additional common SNPs that have not been identified previously. It appears that genetic variation in these five genes has a marginal effect on response to citalopram, although a previously observed association was supported and awaits replication in an independent sample. Pharmacogenetics and Genomics",

keywords = "Association, Citalopram, Fluoxetine, Pharmacogenetics, Single nucleotide polymorphism",

author = "Peters, {Eric J.} and Slager, {Susan L.} and Jenkins, {Greg D.} and Reinalda, {Megan S.} and Garriock, {Holly A.} and Shyn, {Stanley I.} and Kraft, {Jeffrey B.} and McGrath, {Patrick J.} and Hamilton, {Steven P.}",

year = "2009",

month = jan,

doi = "10.1097/FPC.0b013e3283163ecd",

language = "English (US)",

volume = "19",

pages = "1--10",

journal = "Pharmacogenetics and genomics",

issn = "1744-6872",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

AU - Peters, Eric J.

AU - Slager, Susan L.

AU - Jenkins, Greg D.

AU - Reinalda, Megan S.

AU - Garriock, Holly A.

AU - Shyn, Stanley I.

AU - Kraft, Jeffrey B.

AU - McGrath, Patrick J.

AU - Hamilton, Steven P.

PY - 2009/1

Y1 - 2009/1

N2 - Several reports have been published investigating the relationship between common variants in serotonin-related candidate genes and antidepressant response, and most of the results have been equivocal. We previously reported a significant association between variants in serotoninrelated genes and response to the selective serotonin reuptake inhibitor fluoxetine. Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N= 1953). None of the variants associated previously with fluoxetine response were found to be associated with citalopram response in the STAR*D sample set. Nor were any of the additional tagging SNPs found to be associated with citalopram response. An additional SNP in HTR2A (rs7997012), previously reported to be associated with outcome of citalopram treatment in this sample, but not well tagged by any of the other SNPs we studied, was also genotyped, and was associated with citalopram response (P= 0.0002), strongly supporting the previous observation in the same STAR*D sample. Our results suggest that resequencing the serotonin-related genes did not identify any additional common SNPs that have not been identified previously. It appears that genetic variation in these five genes has a marginal effect on response to citalopram, although a previously observed association was supported and awaits replication in an independent sample. Pharmacogenetics and Genomics

AB - Several reports have been published investigating the relationship between common variants in serotonin-related candidate genes and antidepressant response, and most of the results have been equivocal. We previously reported a significant association between variants in serotoninrelated genes and response to the selective serotonin reuptake inhibitor fluoxetine. Here, we attempt to expand upon and replicate these results by (i) resequencing the exonic and putatively regulatory regions of five serotonin-related candidate genes (HTR1A, HTR2A, TPH1, TPH2, and MAOA) in our fluoxetine-treated sample to uncover novel variants; (ii) selecting tagging single nucleotide polymorphisms (SNPs) for these genes from the resequencing data; and (iii) evaluating these tagging SNPs for association with response to the selective serotonin reuptake inhibitor citalopram in an independent sample of participants who are enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical study (N= 1953). None of the variants associated previously with fluoxetine response were found to be associated with citalopram response in the STAR*D sample set. Nor were any of the additional tagging SNPs found to be associated with citalopram response. An additional SNP in HTR2A (rs7997012), previously reported to be associated with outcome of citalopram treatment in this sample, but not well tagged by any of the other SNPs we studied, was also genotyped, and was associated with citalopram response (P= 0.0002), strongly supporting the previous observation in the same STAR*D sample. Our results suggest that resequencing the serotonin-related genes did not identify any additional common SNPs that have not been identified previously. It appears that genetic variation in these five genes has a marginal effect on response to citalopram, although a previously observed association was supported and awaits replication in an independent sample. Pharmacogenetics and Genomics

KW - Association

KW - Citalopram

KW - Fluoxetine

KW - Pharmacogenetics

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=58149216282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149216282&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e3283163ecd

DO - 10.1097/FPC.0b013e3283163ecd

M3 - Article

C2 - 19077664

AN - SCOPUS:58149216282

SN - 1744-6872

VL - 19

SP - 1

EP - 10

JO - Pharmacogenetics and genomics

JF - Pharmacogenetics and genomics

IS - 1

ER -

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this